HuLuc63 exhibits antimyeloma activity in vivo and eradicates tumors in mice. (A-C) Mice with established myeloma xenograft tumors (average of approximately 100 mm³) were randomized into groups 16-21 days after inoculation and were then treated with either a humanized IgG₁ control antibody (□) or HuLuc63 (▲). ▼ indicates the treatment days. Tumor growth results for individual mice are shown over a period of 40 days. Animals were taken off study once the tumors reached a size of greater than 2500 mm³. Group mean tumor volumes were significantly different between HuLuc63 and the control group in (A) the L363 model (P < .04 as of day 26); (B) the OPM2 model (P < .04 as of day 23); and (C) the MM1S model (P < .03 as of day 26). (D) Dose range finding study in the OPM2 model. Mice were randomized when tumors reached approximately 85 mm³ and were treated with control antibody at 10 mg/kg (□) or HuLuc63 at 0.1 mg/kg (♦), 0.5 mg/kg (●), 1 mg/kg (◇), and 10 mg/kg (▲). By day 23, all HuLuc63 groups reached significant difference from the control (with a minimum of P < .04), with the exception of the 0.1 mg/kg group, which was not significantly different from control throughout the study.